Published in J Rheumatol on March 15, 2013
Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol (2014) 1.39
The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology (Oxford) (2014) 0.96
Prevention of rheumatoid arthritis: the very first steps. J Rheumatol (2013) 0.77
Characterization of Autoantigens Targeted by Anti-Citrullinated Protein Antibodies In Vivo: Prominent Role for Epitopes Derived from Histone 4 Proteins. PLoS One (2016) 0.75
Prevalence of musculoskeletal disorders and rheumatic diseases in the indigenous Qom population of Rosario, Argentina. Clin Rheumatol (2016) 0.75
Diversity of the human intestinal microbial flora. Science (2005) 49.64
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA (2006) 6.26
Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc (2004) 5.97
How many duodenal biopsy specimens are required to make a diagnosis of celiac disease? Gastrointest Endosc (2008) 4.58
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology (2010) 3.87
Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol (2010) 3.12
Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol (2010) 2.97
Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol (2003) 2.63
Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour. CMAJ (2007) 2.60
Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol (2007) 2.46
High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut (2006) 2.43
Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol (2009) 2.36
Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol (2011) 2.32
Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 2.31
Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol (2009) 2.22
Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology (2011) 2.22
Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol (2010) 2.21
Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis (2009) 2.15
Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol (2009) 2.05
Oxidation in rheumatoid arthritis. Arthritis Res Ther (2004) 1.96
Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol (2008) 1.92
AGA technical review on osteoporosis in hepatic disorders. Gastroenterology (2003) 1.89
Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum (2004) 1.87
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol (2009) 1.83
World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis (2010) 1.82
Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol (2003) 1.80
Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol (2012) 1.73
The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol (2008) 1.72
Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.63
5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol (2012) 1.61
Pathological reassessment of hyperplastic colon polyps in a city-wide pathology practice: implications for polyp surveillance recommendations. Gastrointest Endosc (2012) 1.60
Colonoscopy and its complications across a Canadian regional health authority. Gastrointest Endosc (2009) 1.56
The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol (2006) 1.52
Role of biological therapy for inflammatory bowel disease in developing countries. Gut (2011) 1.51
Crohn's disease recurrence in a small bowel transplant. Am J Gastroenterol (2004) 1.49
Sexual abuse in irritable bowel syndrome: to ask or not to ask -- that is the question. Can J Gastroenterol (2002) 1.47
Familial seropositive rheumatoid arthritis in North American Native families: effects of shared epitope and cytokine genotypes. J Rheumatol (2005) 1.44
Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis (2010) 1.43
A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol (2009) 1.43
The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol (2012) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Brain-gut interactions in inflammatory bowel disease. Gastroenterology (2012) 1.42
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol (2013) 1.36
Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum (2008) 1.35
A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol (2006) 1.33
A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol (2004) 1.33
A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.32
Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.30
AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol (2010) 1.29
Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 1.28
Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology (2011) 1.24
Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis (2010) 1.22
Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr (2007) 1.20
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 1.20
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol (2009) 1.15
Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol (2006) 1.15
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2009) 1.14
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol (2009) 1.13
A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am J Gastroenterol (2006) 1.10
Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum (2012) 1.09
Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions. Inflamm Bowel Dis (2008) 1.09
Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol (2011) 1.09
The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission. Helicobacter (2004) 1.07
Time trends in colon cancer incidence and distribution and lower gastrointestinal endoscopy utilization in Manitoba. Am J Gastroenterol (2008) 1.06
Age at acquisition of Helicobacter pylori in a pediatric Canadian First Nations population. Helicobacter (2002) 1.05
The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol (2005) 1.05
Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis. J Pharmacol Exp Ther (2010) 1.02
Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol (2009) 1.01
Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol (2005) 1.01
Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol (2004) 1.01
Phylogenetic analysis of inflammatory bowel disease associated Escherichia coli and the fimH virulence determinant. Inflamm Bowel Dis (2009) 1.00
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis (2010) 1.00
Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol (2007) 1.00
Regulation of apoptosis in fibroblast-like synoviocytes by the hypoxia-induced Bcl-2 family member Bcl-2/adenovirus E1B 19-kd protein-interacting protein 3. Arthritis Rheum (2007) 0.99
Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol (2013) 0.99
Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition (2006) 0.99
Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci (2012) 0.98
Association between early childhood otitis media and pediatric inflammatory bowel disease: an exploratory population-based analysis. J Pediatr (2012) 0.98
Health service utilization in IBD: comparison of self-report and administrative data. BMC Health Serv Res (2011) 0.97
Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol (2014) 0.96
Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol (2005) 0.96
Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use? Am J Gastroenterol (2004) 0.96
The importance of recognizing increased cecal inflammation in health and avoiding the misdiagnosis of nonspecific colitis. Am J Gastroenterol (2007) 0.96
Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.96
Direct in situ observation of nanoparticle synthesis in a liquid crystal surfactant template. ACS Nano (2012) 0.95
International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis (2012) 0.94
The information needs and preferences of persons with longstanding inflammatory bowel disease. Can J Gastroenterol (2012) 0.94
Rheumatoid arthritis in a north american native population: longitudinal followup and comparison with a white population. J Rheumatol (2010) 0.94